z-logo
Premium
Serum alpha‐fetoprotein as a marker for the effect of post‐operative radiation therapy and/or chemotherapy in eight cases of ovarian endodermal sinus tumour
Author(s) -
Sell A.,
Søgaard H.,
NørgaardPedersen B.
Publication year - 1976
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910180505
Subject(s) - endodermal sinus tumor , alpha fetoprotein , medicine , chemotherapy , dysgerminoma , yolk sac , immature teratoma , radiation therapy , sinus (botany) , tumor marker , teratoma , pathology , choriocarcinoma , gastroenterology , ovary , cancer , germ cell tumors , biology , embryo , botany , hepatocellular carcinoma , genus , microbiology and biotechnology
The clinical pathological findings of eight cases of ovarian endodermal sinus tumour (yolk sac tumour) are presented. Histological examination in all eight cases showed a typical endodermal sinus tumour pattern, and in six of the patients other tumour elements such as dysgerminoma, choriocarcinoma, malignant teratoma, endometriosis, and a dermoid cyst were also found. Six patients had increased serum alpha‐fetoprotein concentration in the postoperative period, and two patients had a normal concentration 27 and 35 days after operation, respectively. In all cases except one, a close correlation between serum alpha‐fetoprotein and progression or regression of tumour was found. Serum alpha‐fetoprotein was thus found to be a reliable parameter in post‐operative radiation and/or chemotherapy (VAMBLE). In one patient who died 10 months after operation with widespread endodermal sinus tumour growth, only a small terminal increase in serum alpha‐fetoprotein concentration was found. Four of the eight women are still alive with normal alpha‐fetoprotein concentration, and without clinical evidence of tumour disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here